|
|
|
|
|
|
|
|
|
The Wright Reports site is no longer hosted or operated by Manta. Please review
the following:
1. You have been redirected to CorporateInformation.com where you can view
Snapshot reports or purchase Wright reports or subscriptions of your choosing.
2. If you were previously linking to Wright Reports please change your links to
www.corporateinformation.com
3. If you are a paid subscriber with an active subscription please continue on
to the member site:
http://member.corporateinformation.com/home.asp
4. For additional information related to CorporateInformation.com please contact
help@corporateinformation.com, Contact phone nr to be provided later)
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
|
Callisto Pharmaceuticals, Incorporation
Company Snapshot
|
|
Business Description:
Callisto Pharmaceuticals, Incorporation operates in the Pharmaceutical preparations sector. Callisto Pharmaceuticals, Inc. (Callisto) is a development-stage biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), rheumatoid arthritis (RA), acute leukemia and gastrointestinal (GI) disorders and diseases. The Company's drug candidates include SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C); SP-333, a second generation GC-C receptor agonist; Atiprimod is an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activity, and L-Annamycin is a compound from the anthracycline family of anti-cancer drugs, which has therapeutic profile, including activity against drug resistant tumors. The Company operates through two subsidiary companies: Synergy Pharmaceuticals Inc. and Callisto Research Labs, LLC.
|
|
| |
|
| |
|
| |
|
|
|
|
|
|
|
|
| |
| |
Stock Data: |
Recent Stock Performance: |
|
| |
Current Price (2/3/2012):
.29
(Figures in
U.S. Dollars) |
|
1 Week |
26.1% |
|
13 Weeks |
16.0% |
|
|
|
|
|
|
|
|
|
4 Weeks |
-34.1% |
|
52 Weeks |
-55.4% |
|
|
|
| |
| |
Callisto Pharmaceuticals, Incorporation
Key Data: |
|
|
|
| |
Ticker: |
CLSP |
Country: |
UNITED STATES |
| |
|
| |
Exchanges: |
OTC |
Major Industry: |
Miscellaneous |
| |
|
| |
|
|
Sub Industry: |
Service Organizations |
| |
|
| |
2001
Sales |
(Year Ending Jan 2002). |
Employees: |
10 |
| |
|
| |
Currency: |
U.S. Dollars |
Market Cap: |
45,969,661 |
| |
|
| |
Fiscal Yr Ends: |
December |
Shares Outstanding: |
158,516,071 |
| |
|
| |
Share Type: |
Common |
Closely Held Shares: |
40,215,887 |
|
| |
|
| |
| |
|
|
|
CorporateInformation® website and selected data Copyright © 2000 -
by The Winthrop Corporation. All Rights Reserved. Except for quotations by established
news media, no pages on this site may be reproduced, stored in a retrieval system,
or transmitted for commercial purposes, in any form or by any means, electronic,
mechanical, photocopying, recording, or otherwise without prior written permission.
Information is believed reliable, but accuracy, completeness and opinions are not
guaranteed.
|
|
|
|
|